Key Insights

Highlights

Success Rate

71% trial completion

Treatment Research

18 treatments under study, led by Melatonin

Research Leaders

17 sponsors active, led by Brigham and Women's Hospital

Related Conditions

Often studied with 15 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 39/100

Termination Rate

18.2%

2 terminated out of 11 trials

Success Rate

71.4%

-15.2% vs benchmark

Late-Stage Pipeline

36%

4 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed with results

Key Signals

2 with results71% success

Data Visualizations

Phase Distribution

8Total
Not Applicable (3)
Phase 1 (1)
Phase 3 (1)
Phase 4 (3)

Trial Status

Completed5
Recruiting2
Unknown2
Terminated2

Trial Success Rate

71.4%

Benchmark: 86.6%

Based on 5 completed trials

Clinical Trials (11)

Research Network

Common Treatments

  • Melatonin3
  • Constant Routine1
  • Decrease Evening Blue Light1
  • Increase Morning Bright Light1
  • Lemborexant1

Active Sponsors

  • Brigham and Women's Hospital3
  • Stanford University3
  • American Academy of Sleep Medicine1
  • Northwestern University1
  • University of Bergen1

Top Investigators

Related Conditions

  • Sleep Disorders Circadian Rhythm3
  • Delayed Sleep Phase3
  • Advanced Sleep Phase Syndrome Asps3
  • Irregular Sleepwake Syndrome2
  • Shift Work Type Circadian Rhythm Sleep Disorder2

Activity Timeline